Scotia Capital’s Outlook Therapeutics OTLK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.1K Sell
26,300
-20,000
-43% -$19.1K ﹤0.01% 973
2026
Q2
$73.6K Buy
+46,300
New +$28.7K ﹤0.01% 893
2026
Q1
– Sell
-73,989
Closed -$117K – 965
2025
Q4
$117K Hold
73,989
– – ﹤0.01% 866
2025
Q3
$78.4K Hold
73,989
– – ﹤0.01% 887
2025
Q2
$118K Sell
73,989
-50
-0.1% -$80 ﹤0.01% 822
2025
Q1
$90.3K Buy
74,039
+50
+0.1% +$88 ﹤0.01% 814
2024
Q4
$140K Buy
73,989
+41,023
+124% +$169K ﹤0.01% 809
2024
Q3
$176K Hold
32,966
– – ﹤0.01% 783
2024
Q2
$243K Buy
32,966
+9,271
+39% +$74.4K ﹤0.01% 722
2024
Q1
$283K Buy
23,695
+9,491
+67% +$76.7K ﹤0.01% 700
2023
Q4
$112K Sell
14,204
-2,718
-16% -$23K ﹤0.01% 762
2023
Q3
$74.8K Buy
16,922
+13,673
+421% +$303K ﹤0.01% 743
2023
Q2
$113K Buy
+3,249
New +$88.6K ﹤0.01% 746

Other funds holding OTLK

Scotia Capital's OTLK Position: Q3 2026 in Review

Scotia Capital reduced its Outlook Therapeutics (OTLK) stake by 43% in Q3 2026, selling an estimated $19.1K and leaving 26,300 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #973.

Scotia Capital first reported a position in OTLK in Q2 2023 and has held it in 13 quarters since. The position peaked at $283K in Q1 2024. 82 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.

  • Scotia Capital held 26,300 shares of Outlook Therapeutics worth $15.1K as of Q3 2026.
  • Scotia Capital sold 20,000 Outlook Therapeutics shares in Q3 2026, an estimated $19.1K.
  • Outlook Therapeutics made up ﹤0.01% of Scotia Capital's portfolio in Q3 2026, its #973 holding.
  • Scotia Capital first reported a position in Outlook Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Scotia Capital's Outlook Therapeutics position peaked at $283K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.

Based on Scotia Capital's 13F filing for Q3 2026, filed 10 Nov 2026.